Show simple item record

Clinical characteristics and responses of patients with relapsed or refractory high-grade B-Cell lymphoma treated with loncastuximab tesirine in the lotis-2 clinical trial

dc.contributor.authorAlderuccio, J. P.
dc.contributor.authorAi, W. Z.
dc.contributor.authorRadford, John A
dc.contributor.authorSolh, M.
dc.contributor.authorArdeshna, K. M.
dc.contributor.authorLunning, M. A.
dc.contributor.authorHess, B. T.
dc.contributor.authorZinzani, P. L.
dc.contributor.authorStathis, A.
dc.contributor.authorCarlo-Stella, C.
dc.contributor.authorHamadani, M.
dc.contributor.authorKahl, B. S.
dc.contributor.authorUngar, D.
dc.contributor.authorKilavuz, T.
dc.contributor.authorYu, E.
dc.contributor.authorQin, Y.
dc.contributor.authorCaimi, P. F.
dc.date.accessioned2022-10-19T13:13:23Z
dc.date.available2022-10-19T13:13:23Z
dc.date.issued2021en
dc.identifier.citationAlderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, et al. Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413906140.en
dc.identifier.doi10.1182/blood-2021-148730en
dc.identifier.urihttp://hdl.handle.net/10541/625654
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2021-148730en
dc.titleClinical characteristics and responses of patients with relapsed or refractory high-grade B-Cell lymphoma treated with loncastuximab tesirine in the lotis-2 clinical trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FLen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record